MedPage Today: Combination treatment promising for certain leukemia patients

UC expert comments on new study

A combination of low-intensity chemotherapy and an antibody-drug conjugate drug showed promise in a phase 2 trial for older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukemia (ALL).

MedPage Today highlighted the study, and patients in the study had a "significant improvement" in their five-year progression-free survival compared to historical data for this patient set, according to the study's authors.

Emily Curran, MD, medical director of the University of Cincinnati Cancer Center Clinical Trials Office and assistant professor of Internal Medicine in UC's College of Medicine, authored a corresponding commentary on the study, published in The Lancet Hematology.

The study "provides impressive results, with survival outcomes that far exceed historic survival data in older adults with acute lymphocytic leukemia," Curran wrote in the commentary.

Read the MedPage Today article.

Featured photo at top: Dr. Emily Curran examines specimens using a microscope in her lab. Photo/Colleen Kelley/UC Marketing + Brand.

Related Stories